Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S095035 as Single Agent and in Combination in MTAP-Deleted Solid Tumors
NCT06188702Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of s095035 in solid tumor, non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), gastroesophageal junction cancer, sponsored by Servier. Started Apr 2024; status: active, not recruiting.
02
Drugs
s095035
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)biliary tract cancer (BTC)pancreatic ductal adenocarcinoma (PDAC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06188702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188702.